Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.



Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.

Contact SupportLog In

european medicines agency cover image
$599
Posted in: Bolus Insulin, GLP-1RA Jan 31 | 2020Rybelsus and URLi Receive Positive CHMP OpinionsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 31 | 2020Thoughts on New CVS Program to Eliminate Diabetes Drug OOP CostsPurchase Blast
lilly cover image
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, SGLT2i Jan 30 | 2020Lilly and Roche Q4 '19 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Jan 28 | 2020Lilly to Donate Insulin Pens; Fractyl Launches Revita DMR in the UKPurchase Blast
european medicines agency cover image
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucagon, SGLT2i Jan 27 | 2020Oral Semaglutide and URLi CHMP Opinions Anticipated; Forxiga Lower-limb Warning?; Xeris Gvoke Filed (CHMP Agenda January 27-30)Purchase Blast
$599
Posted in: Glucose Monitoring Jan 27 | 2020i-SENS Receives FDA Clearance for Another BT BGMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal Jan 14 | 2020JPM 2020 Day 2: LLY, NVO, LVGO, SNY, PODD, ABT, and BDPurchase Blast
ADA cover image
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 03 | 2020Thoughts on ADA 2020 Standards of CarePurchase Blast
1 65 66 67 68 69 99